Impact of hypoxic hepatitis on mortality in the intensive care unit
- 545 Downloads
Hypoxic hepatitis (HH) is a form of hepatic injury following arterial hypoxemia, ischemia, and passive congestion of the liver. We investigated the incidence and the prognostic implications of HH in the medical intensive care unit (ICU).
A total of 1,066 consecutive ICU admissions at three medical ICUs of a university hospital were included in this prospective cohort study. All patients were screened prospectively for the presence of HH according to established criteria. Independent risk factors of mortality in this cohort of critically ill patients were identified by a multivariate Poisson regression model.
A total of 118 admissions (11%) had HH during their ICU stay. These patients had different baseline characteristics, longer median ICU stay (8 vs. 6 days, p < 0.001), and decreased ICU survival (43 vs. 83%, p < 0.001). The crude mortality rate ratio of admissions with HH was 4.62 (95% CI 3.63–5.86, p < 0.001). Regression analysis demonstrated strong mortality risk for admissions with HH requiring vasopressor therapy (adjusted rate ratio 4.91; 95% CI 2.51–9.60, p < 0.001), whereas HH was not significantly associated with mortality in admissions without vasopressor therapy (adjusted rate ratio 1.79, 95% CI 0.52–6.23, p = 0.359).
Hypoxic hepatitis (HH) occurs frequently in the medical ICU. The presence of HH is a strong risk factor for mortality in the ICU in patients requiring vasopressor therapy.
KeywordsHypoxic liver injury Ischemic hepatitis Shock liver Mortality Vasopressors Epidemiology Outcome
Serum alanine transaminase
Serum aspartate transaminase
Intensive care unit
Simplified acute physiology score
- 3.Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Kitzberger R, Warszawska J, Holzinger U, Schenk P, Madl C (2009) Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 35:1397–1405PubMedCrossRefGoogle Scholar
- 8.Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 93:841–842PubMedCrossRefGoogle Scholar
- 9.Gibson PR, Dudely F (1984) Ischemic hepatitis: clinical features, diagnosis and prognosis. Aust N Z J Med 14:825–922Google Scholar
- 15.Gillum BS, Graves E, Kozak LJ (1989) Vital and health statistics. Trends in hospital utilization: United States 1965–86. Vital Health Stat 13:1–57Google Scholar
- 28.Peralta C, Perales JC, Bartrons R, Mitchell C, Gilgenkrantz H, Xaus C, Prats N, Fernández L, Gelpí E, Panés J, Roselló-Catafau J (2002) The combination of ischemic preconditioning and liver Bcl-2 over expression is a suitable strategy to prevent liver and lung damage after hepatic ischemia–reperfusion. Am J Pathol 160:2111–2122PubMedCrossRefGoogle Scholar
- 38.Casillas-Ramirez A, Amine-Zaouali M, Massip-Salcedo M, Padrissa-Altés S, Bintanel-Morcillo M, Ramalho F, Serafín A, Rimola A, Arroyo V, Rodés J, Roselló-Catafau J, Peralta C (2008) Inhibition of angiotenin II action protects steatotic liver against ischemia–reperfusion injury. Crit Care Med 36:1256–1266PubMedCrossRefGoogle Scholar
- 40.Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, Liu Y, Jhala N, Crowe DR, Smith AB, Cross RC, Frenette L, Kelley EE, Wilhite DW, Hall CR, Page GP, Fallon MB, Bynon JS, Eckhoff DE, Patel RP (2007) Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 117:2583–2591PubMedCrossRefGoogle Scholar